Role of CD11b and its Mean Fluorescence Intensity for Follow up of Cirrhotic Ascitic Patents with Spontaneous Bacterial Peritonitis and Their Response to Treatment

Document Type : Original Article

Authors

1 Hepatology unit, department of internal medicine, Faculty of Medicine, Mansoura University

2 Prof. of Hepatology unit, department of internal medicine, Faculty of Medicine, Mansoura University

3 Prof. of Department of clinical pathology, Faculty of Medicine, Mansoura University

4 Prof. of Liver transplantation program, Gastrointestinal Surgery Center, Department of Surgery, Faculty of Medicine, Mansoura University

Abstract

Back ground: Spontaneous bacterial peritonitis (SBP) is a common and high-mortality infectious complication of patients with cirrhosis. This study aims to evaluate the neutrophil surface receptor CD11b as a marker for detecting SBP and predicting mortality after SBP. Patients and methods: Ninety adult patients were recruited from the hepatology gastroenterology department, Mansoura University Hospitals, and Mahalla Hepatology Teaching Hospital, blood CD11b, and the mean fluorescence intensity (MFI) were tested as a marker for the detection and follow up of SBP. Results: CD11b was higher in the SBP group vs. control group but this difference was not statistically significant by pairwise comparison. Moreover, the study revealed that CD11b is a non-discriminating marker in our cases. MFI was a statistically significant discriminator for G1 vs. G3, G2 vs. G3, G1-2 vs. G3. Finally, the study revealed a statistically significantly higher age, MFI of CD11b, WBCs, Neutrophils, NLR, creatinine, higher positive CRP, CRP/ Albumin ratio >3.5, MELD score >21, higher Child Pugh score and ICU admission and a statistically significantly lower SBP, DBP, MAP, Hb, albumin and CD11b / CRP ratio in non-survivors (less than 3 months) versus survivors. Conclusion: In cirrhotic patients CD11b-MFI can discriminate between ascitic and non ascitic cases but cannot discriminate between SBP and non-SBP cases. It can be implied as new biomarker to follow up SBP cases and evaluate antibiotic response in those patients.

Keywords